|
|
Approximately
5% of patients who take abacavir experience this reaction
and symptoms can include rash, fever, fatigue, and malaise
(generally ill feeling, among others). These symptoms
generally occur during the first 6 weeks of treatment.
|
|
Objective
|
GlaxoSmithKline
(the study sponsor) is looking at the genes, proteins
and other blood factors that may be involved in the hypersensitivity
reaction (serious allergy reaction). They will compare
information from volunteers who experienced this reaction
to information from individuals who did not. The long
term objective is to develop a test that will predict
abacavir sensitivity. |
|
|
This
study does not involve a drug and only involves two
clinic visits, blood draws, and a confidential interview.
Volunteers will be compensated $50 for their inconvenience
after both clinic visits are completed. |
|
Inclusion
Criteria
|
-
HIV+ adult male or female
- Documented
abacavir hypersensitivity reaction (medical or case
management records)
|
|
Status
__
|
Enrolling
--
|
Volunteers
will receive $50 compensation for their inconvenience
after both clinic visits are completed..
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS ReSearch Alliance
Institutional Review Board in April, 2002.
|
